CA3157394A1 - Compounds for treatment of eye diseases associated with excessive vascularisation - Google Patents

Compounds for treatment of eye diseases associated with excessive vascularisation Download PDF

Info

Publication number
CA3157394A1
CA3157394A1 CA3157394A CA3157394A CA3157394A1 CA 3157394 A1 CA3157394 A1 CA 3157394A1 CA 3157394 A CA3157394 A CA 3157394A CA 3157394 A CA3157394 A CA 3157394A CA 3157394 A1 CA3157394 A1 CA 3157394A1
Authority
CA
Canada
Prior art keywords
composition
neovascularisation
eye
use according
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3157394A
Other languages
English (en)
French (fr)
Inventor
Helena ERIKSSON
Joel Kaye
Marie Torngren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of CA3157394A1 publication Critical patent/CA3157394A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3157394A 2019-12-19 2020-12-18 Compounds for treatment of eye diseases associated with excessive vascularisation Pending CA3157394A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19218062.8 2019-12-19
EP19218062 2019-12-19
EP20156158.6 2020-02-07
EP20156158 2020-02-07
PCT/EP2020/086993 WO2021123142A1 (en) 2019-12-19 2020-12-18 Compounds for treatment of eye diseases associated with excessive vascularisation

Publications (1)

Publication Number Publication Date
CA3157394A1 true CA3157394A1 (en) 2021-06-24

Family

ID=74141502

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3157394A Pending CA3157394A1 (en) 2019-12-19 2020-12-18 Compounds for treatment of eye diseases associated with excessive vascularisation

Country Status (15)

Country Link
US (2) US11478465B2 (https=)
EP (2) EP3886858B1 (https=)
JP (1) JP7730816B2 (https=)
KR (1) KR20220118419A (https=)
CN (1) CN114845718B (https=)
AU (1) AU2020408179B2 (https=)
BR (1) BR112022009192A2 (https=)
CA (1) CA3157394A1 (https=)
DK (1) DK3886858T3 (https=)
ES (1) ES2921360T3 (https=)
IL (1) IL293469B2 (https=)
MX (1) MX2022006439A (https=)
PL (1) PL3886858T3 (https=)
WO (1) WO2021123142A1 (https=)
ZA (1) ZA202204939B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
KR20220118419A (ko) * 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물
PL4312986T3 (pl) 2021-04-01 2025-02-17 Active Biotech Ab Preparat lakwinimodu do stosowania do oczu
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
AU2024306742A1 (en) * 2023-06-28 2025-12-04 Active Biotech Ab Quinoline carboxamides for use in the treatment of mpn
CN117256554A (zh) * 2023-09-08 2023-12-22 益诺思生物技术南通有限公司 一种c57bl/6j小鼠新生血管型眼病模型及其构建方法
KR102925647B1 (ko) * 2023-10-13 2026-02-11 재단법인 대구경북첨단의료산업진흥재단 안질환 치료제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
WO2010070449A2 (en) 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2012006538A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
IN2014MN00333A (https=) 2011-07-28 2015-09-25 Teva Pharma
US20150111833A1 (en) * 2012-04-20 2015-04-23 Howard University Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease
EP2849762A4 (en) 2012-05-16 2016-02-24 Aadigen Llc MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY DISORDERS
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
CN109432073A (zh) 2013-01-08 2019-03-08 帕萨罗杰卡有限公司 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
EP3019526A1 (en) * 2013-07-11 2016-05-18 Novartis AG Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
WO2015060812A1 (en) 2013-10-21 2015-04-30 Howard University Treating ocular disease with efflux transporter inhibitors
EP3068395A4 (en) 2013-11-15 2017-07-12 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
CA2933900A1 (en) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
WO2017120355A1 (en) 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
CA3010862A1 (en) 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
JP2020528082A (ja) * 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
WO2019126424A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
BR112020019822A2 (pt) 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar
KR20220118419A (ko) * 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물

Also Published As

Publication number Publication date
PL3886858T3 (pl) 2022-08-29
EP3886858B1 (en) 2022-05-11
ZA202204939B (en) 2023-12-20
US12208091B2 (en) 2025-01-28
EP4094765A1 (en) 2022-11-30
DK3886858T3 (da) 2022-08-22
ES2921360T3 (es) 2022-08-24
CN114845718A (zh) 2022-08-02
KR20220118419A (ko) 2022-08-25
IL293469A (en) 2022-08-01
CN114845718B (zh) 2025-05-16
MX2022006439A (es) 2022-07-19
WO2021123142A1 (en) 2021-06-24
BR112022009192A2 (pt) 2022-07-26
EP3886858A1 (en) 2021-10-06
US20230066364A1 (en) 2023-03-02
US20210322400A1 (en) 2021-10-21
AU2020408179A1 (en) 2022-06-30
JP7730816B2 (ja) 2025-08-28
IL293469B1 (en) 2023-12-01
JP2023509336A (ja) 2023-03-08
US11478465B2 (en) 2022-10-25
AU2020408179B2 (en) 2025-04-10
IL293469B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
AU2020408179B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
AU2023251388B2 (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
Donnenfeld et al. Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study
CN105377891A (zh) Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用
RS62827B1 (sr) Tretman staračke degeneracije žute mrlje koja ima malu aktivnu leziju neovaskularizacije sudovnjače
Van Bergen et al. Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery
US12102640B2 (en) Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
JP2008029346A (ja) 糖尿病黄斑症の予防又は治療剤
JP2019524880A (ja) マルチキナーゼ阻害剤
TW200815416A (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
Kuerten et al. Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model
CN105555364A (zh) 炎症性眼科疾病的局部治疗
Galor et al. Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery
AU2021395633A1 (en) Eyedrops for treating scleral thinning and screening method for therapeutic agent of scleral thinning
JP6835836B2 (ja) 脈絡膜血管新生の処置のための方法及び医薬組成物
Gillies et al. Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40061312A (en) Compounds for treatment of eye diseases associated with excessive vascularisation
EA045318B1 (ru) Соединения для лечения глазных болезней, связанных с избыточной васкуляризацией
Ghule et al. Intravitreal Bevacizumab (Avastin) Alone Or With Laser Photocoagulation for Diabetic Macular Edema
Ferrer et al. Ophthalmic therapeutics: new basic research and clinical studies
Arias et al. Highlights from the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2011: Visionary Genomics

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241119

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241119

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PPH

Effective date: 20241223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250219

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250224

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250325

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D17-D112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PPH

Effective date: 20250430

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D161 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PPH RETAINED AFTER REVIEW

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250506

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250513

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250911

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251229

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251229

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251229

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128